Mark Nathan Lampert, founder of the Biotechnology Value Fund (BVF). See contact routes.
Mark Nathan Lampert, founder of the Biotechnology Value Fund (BVF), invests primarily in small-cap biotechnology companies (market caps $100M–$1B) using a value-oriented thesis that targets undervalued assets with strong scientific or clinical potential. His firm builds concentrated, long-term equity positions in early-stage drug development and clinical-stage biopharma, often engaging constructively with management to unlock value. Notable portfolio companies include Blueprint Medicines, Kymera Therapeutics, Xencor, Molecular Partners, and ChemoCentryx, with Kymera (KYMR) representing his largest holding at $458.3M as of Q1 2026. While BVF is primarily a hedge fund focused on public securities, it also participates in private venture rounds, such as a $52M Series A investment in Third Arc Bio in February 2026.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in San Francisco.
Investors like Mark Nathan Lampert · Full investor directory · Investor access · Company funding database